All Photos(1)

Documents

SML3224

Sugammadex sodium

Name: Sugammadex sodium
Brand: SIGMA

≥95% (HPLC), powder, neuromuscular blocker reversing agent

Synonym(s):

6-Perdeoxy-6-per(2-carboxyethyl)thio-γ-cyclodextrin, sodium Salt, Org 25969, Org-25969, Org25969

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₇₂H₁₀₄Na₈O₄₈S₈

CAS Number:

343306-79-6

Molecular Weight:

2178.01

MDL number:

MFCD09954145

UNSPSC Code:

12352107

NACRES:

NA.77

product name

Sugammadex sodium, ≥95% (HPLC)

Quality Level

100

Assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

H₂O: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](CSCCC(O[Na])=O)O[C@H](O[C@@H]3[C@@H](CSCCC(O[Na])=O)O[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@@H]5[C@@H](CSCCC(O[Na])=O)O[C@H](O[C@@H]6[C@@H](CSCCC(O[Na])=O)O[C@H]7[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)O[C@@H]4CSCCC(O[Na])

InChI

1S/C72H112O48S8.8Na/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90;;;;;;;;/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88);;;;;;;;/q;8*+1/p-8/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-;;;;;;;;/m1......../s1

InChI key

KMGKABOMYQLLDJ-VKHHSAQNSA-F

Biochem/physiol Actions

Sugammadex (Org 25969) is a selective relaxant binding agent (SRBA) for complexing aminosteroid nonpolarizing neuromuscular blockers (NMBs), including pipecuronium, rocuronium and vecuronium. Sugammadex effectively recovers muscle twitch blockade in vitro (EC50 = 1.2 μM, Emax = 95.1%; isolated mouse hemi-diaphragm under 90% block by 3.6 μM rocuronium) and reverses neuromuscular blockade in vivo (ED50 = 30 nmol/kg i.v. & Emax = 92.5% with guinea pigs under 90% neuromuscular block by 10 nmol/kg/min rocuronium i.v. infusion; >90% recovery at 1 mg/kg or 0.46 μmol/kg i.v. of M. tibialis contractions of cats under 95% block by 10.24 nmol/kg/min rocuronium i.v. infusion).

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.

Julia M Adam et al.

Journal of medicinal chemistry, 45(9), 1806-1816 (2002-04-19)

A series of mono- and per-6-substituted cyclodextrin derivatives were synthesized as synthetic receptors (or host molecules) of rocuronium bromide, the most widely used neuromuscular blocker in anaesthesia. By forming host-guest complexes with rocuronium, these cyclodextrin derivatives reverse the muscle relaxation

Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys.

Hans D de Boer et al.

Anesthesiology, 104(4), 718-723 (2006-03-31)

Reversal of neuromuscular blockade can be accomplished by chemical encapsulation of rocuronium by sugammadex, a synthetic gamma-cyclodextrin derivative. The current study determined the feasibility of reversal of rocuronium-induced profound neuromuscular blockade with sugammadex in the anesthetized rhesus monkey using train-of-four

Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats.

Tünay Kandemir et al.

Turkish journal of anaesthesiology and reanimation, 47(5), 392-395 (2019-10-02)

In an in vitro study, lidocaine, remifentanil and methylprednisolone produced inclusion complexes with sugammadex, which lead to a decrease in free and active concentrations of sugammadex. When used concurrently with these drugs, it is likely that the time for sugammadex

Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys.

H D de Boer et al.

British journal of anaesthesia, 96(2), 201-206 (2005-12-27)

At present, reversal of neuromuscular block induced by steroidal neuromuscular blocking agents (NMBAs) is achieved by administration of cholinesterase inhibitors. Chemical encapsulation of steroidal NMBAs, such as rocuronium, by a cyclodextrin is a new concept in neuromuscular block reversal. The

Effect of protracted dexamethasone exposure and its withdrawal on rocuronium-induced neuromuscular blockade and sugammadex reversal: an ex vivo rat study.

Seok Kyeong Oh et al.

Scientific reports, 9(1), 11268-11268 (2019-08-04)

Studies have reported that protracted dexamethasone treatment induces resistance to nondepolarizing neuromuscular blocking agents (NMBAs) and the association with nicotinic acetylcholine receptors in the diaphragm of rats. Here, we investigated the effect of protracted dexamethasone administration on the sensitivity to

View All Related Papers